#USA #New Haven #XingImaging #Alzheimer's Tau Platform #Tau PET Imaging

XingImaging's Landmark Selection as Imaging Core Lab for Alzheimer's Research

XingImaging, a renowned neuroimaging and radiopharmaceutical services provider, has been designated as the Imaging Core Lab for the groundbreaking Alzheimer's Tau Platform (ATP)—a multi-arm, randomized Phase II clinical trial. This pivotal study, backed by the National Institutes of Health, aims to explore tau-directed therapies in both preclinical and prodromal Alzheimer's disease stages. The ATP trial plans to enroll up to 750 participants across roughly 78 clinical sites throughout the United States. It stands as one of the most ambitious imaging-focused interventional studies ever undertaken in Alzheimer's research.

Focus of the Alzheimer’s Tau Platform Trial

The ATP trial is primarily designed to assess if tau-targeted therapies can effectively reduce tau accumulation in the brain compared to anti-amyloid therapies. A significant aspect of the study is the use of tau PET imaging, which constitutes the trial's primary endpoint for evaluating outcomes. Moreover, the integration of quantitative amyloid PET imaging further adds to the trial's depth by providing a baseline for detecting Alzheimer’s pathology.

As the Imaging Core Lab, XingImaging will spearhead the oversight of all PET imaging operations. Dr. Roger Gunn, Chief Scientific Officer at XingImaging, expressed his enthusiasm about the study, stating, “Quantitative tau PET is at the heart of the ATP trial, and we are delighted to serve as the Imaging Core Lab for a study of such scientific and clinical significance.”

The Scientific Rigor of the ATP Trial

The participating individuals in the ATP trial range from ages 50 to 80, and all have been confirmed to possess late preclinical or early prodromal Alzheimer’s through the analysis of plasma biomarkers and elevated tau and amyloid PET. Dr. Keith Johnson, the Co-Principal Investigator, noted, “The ATP trial represents a new generation of Alzheimer's disease therapeutic studies—those that depend on sensitive, quantitative biomarkers to gain unprecedented insight into treatment impacts.” He emphasized the crucial role of tau PET imaging in revealing the main pathology that leads to cognitive decline, while amyloid PET provides an intricate characterization of amyloid levels in the brain.

Integrating Advanced Imaging Capabilities

As the ATP platform progresses towards its goals, delivering high-quality molecular imaging becomes even more essential. XingImaging’s advanced PET imaging capabilities will ensure the precision and consistency needed for a study of this magnitude. “This is precisely the type of platform where high-quality, quantitative imaging can dramatically enhance therapeutic discovery,” stated Gilles Tamagnan, CEO of XingImaging.

XingImaging’s commitment includes providing operational excellence, imaging science, and advanced analytical capabilities that are crucial for promising next-generation therapeutic developments for Alzheimer’s disease.

About XingImaging

Based in New Haven, Connecticut, XingImaging has developed a reputation as a key player in the field of neuroimaging and radiopharmaceuticals, backed by an expansive facility covering over 24,000 square feet and staffed by over 60 scientists and experts in various relevant fields. This infrastructure allows for robust clinical operations, chemical analysis, imaging science, regulatory affairs, quality assurance, and data management, offering comprehensive support for both early and late-stage therapeutic development programs.

As part of its participation in the ATP trial, XingImaging looks forward to leveraging its expertise to contribute meaningfully to the fight against Alzheimer’s disease. With ambitious plans and cutting-edge methodologies, this collaboration could pave the way for groundbreaking advancements in the understanding and treatment of this debilitating condition.